Agilent Plans to Buy Varian for $1.5 Billion to Expand Footprint in Life Sciences
July 30, 2009
Agilent Plans to Buy Varian for $1.5 Billion to Expand Footprint in Life Sciences
The acquisition is Agilent's largest in the life sciences space and continues a strategy by the firm to focus on that segment and its "transformation into a leading bio-analytical measurement company," its chief executive said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Agilent Expects Varian to Add $111M to Life-Sci Arm's H2 Revenue, May Be a Year for Large M&A
May 21, 2010 / ProteoMonitor - Bruker Completes $37.5M Acquisition of Three Varian Product Lines from Agilent
May 21, 2010 / ProteoMonitor - Bruker Paying $37.5M for Varian's ICP-MS, Lab GC, GC-QQQ-MS Businesses
March 19, 2010 / ProteoMonitor - Recent Deals Suggest Proteomics, Life-Science Markets May be Poised to Renew M&A Activity
September 24, 2009 / ProteoMonitor - Agilent Q3 Revenues Rise 22 Percent as Mass Spec Performs 'Exceptionally Well'
August 19, 2011 / ProteoMonitor